We are live on ! Find out more

1,888 hedge funds and large institutions have $147B invested in Pfizer in 2015 Q2 according to their latest regulatory filings, with 102 funds opening new positions, 695 increasing their positions, 841 reducing their positions, and 72 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more first-time investments, than exits

New positions opened: 102 | Existing positions closed: 72

39% more call options, than puts

Call options by funds: $1.89B | Put options by funds: $1.36B

1% more funds holding

Funds holding: 1,8771,888 (+11)

1.53% less ownership

Funds ownership: 76.39%74.86% (-1.5%)

5% less capital invested

Capital invested by funds: $155B → $147B (-$8.13B)

12% less funds holding in top 10

Funds holding in top 10: 310272 (-38)

17% less repeat investments, than reductions

Existing positions increased: 695 | Existing positions reduced: 841

Holders
1,888
Holders Change
+11
Holders Change %
+0.59%
% of All Funds
50.62%
Holding in Top 10
272
Holding in Top 10 Change
-38
Holding in Top 10 Change %
-12.26%
% of All Funds
7.29%
New
102
Increased
695
Reduced
841
Closed
72
Calls
$1.89B
Puts
$1.36B
Net Calls
+$526M
Net Calls Change
-$149M

PFE Hedge Fund Activity: Q2 2015 in Review

1,888 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2015, worth a combined $147B — down 5.3% from $155B a quarter earlier.

Buyers outnumbered sellers: 102 funds opened new PFE positions and 72 closed out — a net gain of 30 holders — while 695 added to existing stakes and 841 trimmed.

The largest buyer was AJO LP, adding an estimated $635M. The largest seller was Goldman Sachs, cutting an estimated $895M.

  • 1,888 institutional investors held Pfizer (PFE) as of Q2 2015, up from 1,877 in Q1 2015.
  • Funds reported $147B of Pfizer stock for Q2 2015, down 5.3% quarter-over-quarter.
  • 102 funds opened new Pfizer positions in Q2 2015 and 72 closed out, a net change of +30 holders.
  • The largest Pfizer buyer in Q2 2015 was AJO LP, an estimated $635M added.
  • The largest Pfizer seller in Q2 2015 was Goldman Sachs, an estimated $895M sold.

Based on aggregated 13F filings for Q2 2015.